Sign In
Buy GILD
$125.05
+0.180 (+0.144%)
At Close: Jun 23, 2026
Gilead Sciences (GILD) Stock Slides as Market Rises: Facts to Know Before You Trade
07:06pm, Tuesday, 24'th Sep 2024
In the closing of the recent trading day, Gilead Sciences (GILD) stood at $83.79, denoting a -0.24% change from the preceding trading day.
Top 4 Health Care Stocks That May Keep You Up At Night
08:51am, Tuesday, 24'th Sep 2024
As of Sept. 24, 2024, four stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
3 Dirt Cheap Stocks to Buy Right Now
07:36am, Saturday, 21'st Sep 2024
CRISPR Therapeutics is still in its early stages of growth. Gilead Sciences remains an underrated stock.
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields
09:00am, Friday, 20'th Sep 2024
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
10:05am, Thursday, 19'th Sep 2024
Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Gilead Sciences stock nears its all-time high: buy or sell?
12:08am, Thursday, 19'th Sep 2024
Gilead Sciences (GILD) stock price has staged a strong comeback this year, helped by strong earnings and a recent $40 million settlement with American authorities. It has risen for two consecutive wee
Gilead Sciences (GILD) Stock Sinks As Market Gains: Here's Why
07:06pm, Tuesday, 17'th Sep 2024
The latest trading day saw Gilead Sciences (GILD) settling at $83.08, representing a -0.1% change from its previous close.
Got $200? 2 Healthcare Stocks to Buy and Hold Forever
08:45am, Saturday, 14'th Sep 2024
Bristol Myers Squibb and Gilead Sciences are longtime healthcare leaders. Both have the innovative abilities needed to continue developing new drugs.
Gilead Stock Rises as HIV Prevention Injection Meets Study Goals
01:56pm, Friday, 13'th Sep 2024
GILD reports the success of its twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir, in a second late-stage study for the prevention of HIV.
Why Gilead Sciences Stock Thrashed the Market Today
06:11pm, Thursday, 12'th Sep 2024
Lenacapavir, one of several HIV drugs in Gilead's portfolio, met its key endpoints in a late-stage clinical trial. It did even better than Gilead's classic HIV treatment.
Gilead's HIV-prevention drug cut infections by 96%, boosting stock
10:00am, Thursday, 12'th Sep 2024
Gilead's twice-yearly injection for HIV prevention cut infections by 96% in a late-stage trial, the company said Thursday, building the case for regulatory approval of the treatment.
Gilead's twice-yearly shot cut HIV infections by 96% in trial
09:29am, Thursday, 12'th Sep 2024
Gilead's twice-yearly shot reduced HIV infections by 96% in a second large study, the company said Thursday. The data sets the stage for likely FDA approval of Lenacapavir for HIV prevention.
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the results of an interim analysis from a second pivotal Phase 3 clinical trial investigating the use of the
Gilead Sciences, Inc. (GILD) Baird Global Healthcare Conference (Transcript)
08:00pm, Tuesday, 10'th Sep 2024
Gilead Sciences, Inc. (NASDAQ:GILD ) Baird Global Healthcare Conference September 10, 2024 10:50 PM ET Company Participants Johanna Mercier - Chief Commercial Officer Conference Call Participants Bria
Undercovered Dozen: EPR Properties, Gilead, Portland General Electric, CNH Industrial +
01:15pm, Friday, 06'th Sep 2024
The 'Undercovered' Dozen series highlights 12 lesser-known stocks, offering fresh investment ideas and encouraging community discussion on their potential. Gen Alpha argues that EPR Properties, a dive
